Search

Your search keyword '"Qiu, Jiwan"' showing total 2 results
Start Over Author "Qiu, Jiwan" Topic interleukin-17
2 results on '"Qiu, Jiwan"'

1. Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody.

Author

Chen W, Kong Y, Li W, Zhou Y, Wu M, Chen T, Wu Y, Qiao H, Qiu Z, and Qiu J

Subjects
Animals, Antibodies, Monoclonal, Humanized immunology, Chemokine CXCL1 immunology, Chemotactic Factors immunology, Dose-Response Relationship, Drug, Humans, Interleukin-6 immunology, Interleukin-8 immunology, Keratinocytes immunology, Macaca mulatta, Mice, Rabbits, Signal Transduction, Antibodies, Monoclonal, Humanized pharmacokinetics, Autoimmune Diseases drug therapy, Interleukin-17 immunology
Abstract

Interleukin-17A (IL-17A) produced by Th17 cells, contributes to the pathogenesis of various autoimmune diseases by stimulating the release of cytokines and chemokines and its regulation. Anti-IL-17A antibody which blocks the function of IL-17A has been proved to be an effective treatment of autoimmune disease. The aim of our study was to generate a potential humanized anti-IL-17A therapeutic monoclonal antibody (mAb) through a comprehensive panel of in vitro and in vivo biological activity studies, as well as physicochemical characterization. HZD37-5, a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A, binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and G-GSF. In an in vivo efficacy mouse model, HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant (KC) secretion in a dose-dependent manner. The pharmacokinetics (PK) study result of HZD37-5 in rhesus monkeys indicated that HZD37-5 had favorable PK characteristics with limited distribution (78.0-78.8 ml/kg), slow elimination (5.00-6.45 ml/day/kg), long half-life (9.1-10.7 days) and high bioavailability (103%) following a single IV or SC dose at 1.5 mg/kg. These findings provided a comprehensive preclinical characterization of HZD37-5 and supported that it may be developed as a potential therapeutic for the treatment of autoimmune diseases, including psoriasis, psoriatic arthritis, axial spondyloarthritis, etc., (Copyright © 2021 Elsevier Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

2. Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody

Author

Yi Zhou, Meijuan Wu, Wu Yiliang, Qiu Jiwan, Qiu Zhihua, Li Wang, Chen Wei, Kong Yong, Chen Tao, and Qiao Huaiyao

Subjects
Keratinocytes, Chemokine, medicine.drug_class, Chemokine CXCL1, Pharmacology, Monoclonal antibody, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Mice, Pharmacokinetics, In vivo, medicine, Animals, Humans, Autoimmune disease, biology, Chemotactic Factors, Dose-Response Relationship, Drug, business.industry, Interleukin-6, Interleukin-17, Interleukin-8, Biological activity, medicine.disease, Macaca mulatta, In vitro, biology.protein, Rabbits, Antibody, business, Biotechnology, Signal Transduction
Abstract

Interleukin-17A (IL-17A) produced by Th17 cells, contributes to the pathogenesis of various autoimmune diseases by stimulating the release of cytokines and chemokines and its regulation. Anti-IL-17A antibody which blocks the function of IL-17A has been proved to be an effective treatment of autoimmune disease. The aim of our study was to generate a potential humanized anti-IL-17A therapeutic monoclonal antibody (mAb) through a comprehensive panel of in vitro and in vivo biological activity studies, as well as physicochemical characterization. HZD37-5, a humanized monoclonal antibody specifically recognizing N78 loci of IL-17A, binds to human and rhesus monkeys, blocks IL-17 induced signal transduction and the release of IL-6, IL-8, CXCL-1 and G-GSF. In an in vivo efficacy mouse model, HZD37-5 significantly inhibited human IL-17A induced-keratinocyte chemoattractant (KC) secretion in a dose-dependent manner. The pharmacokinetics (PK) study result of HZD37-5 in rhesus monkeys indicated that HZD37-5 had favorable PK characteristics with limited distribution (78.0–78.8 ml/kg), slow elimination (5.00–6.45 ml/day/kg), long half-life (9.1–10.7 days) and high bioavailability (103%) following a single IV or SC dose at 1.5 mg/kg. These findings provided a comprehensive preclinical characterization of HZD37-5 and supported that it may be developed as a potential therapeutic for the treatment of autoimmune diseases, including psoriasis, psoriatic arthritis, axial spondyloarthritis, etc.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results